EDUCATION

Undergraduate Degree

  • Massachusetts College of Pharmacy and Health Science , Boston , MA

Graduate Degree

  • Massachusetts College of Pharmacy and Health Science , Boston , MA

Philosophy of Care

It was during a trip to the college fair that a career in pharmacy was first introduced to me. Over time I got more involved in science and medicine and even planned on going to medical school; however, I became drawn to pediatric pharmacy practice, nutrition support in particular. I like the challenges of trying to optimize a child's medication regimen which may mean stopping meds or creating something from scratch. I now have a 36+ year career in pediatric pharmacy and it's been one of the best decisions I've ever made.

PROFESSIONAL HISTORY

Dr. Kathleen Gura is a native New Englander and attended the Massachusetts College of Pharmacy and Health Sciences for both her BS and PharmD degrees. She graduated both programs with high honors.

Upon graduation, Dr. Gura went to Washington, DC for 2 years to work as a clinical pharmacist at Children's National Medical Center. It was there she learned her nutrition basics. She returned to Boston in 1984 and joined the pharmacy staff at BCH. During this time, she also completed a fellowship in clinical nutrition at the University of Florida and became one of the first board certified nutrition support pharmacists in Boston. She has been a member of the Clinical Nutrition program since 1986 and CAIR since its inception.

Today, Dr. Gura is an active member of the American Society for Parenteral and Enteral Nutrition (ASPEN), the American Society for Health System Pharmacists (ASHP) and the Pediatric Pharmacy Advocacy Group (PPAG). She was awarded the ASHP Drug Therapy Research Award as well as the Outstanding Pharmacist and Serlick Award for Safe Practices by ASPEN. Her research focuses on PN associated liver disease, intestinal failure, and lipid emulsions. Her work has been funded by the March of Dimes and the FDA's Orphan Drug Development Program.

CERTIFICATIONS

  • Board of Pharmacy Specialties, Nutrition Support Pharmacist

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Recommendations for photoprotection of parenteral nutrition for premature infants: An ASPEN position paper. Nutr Clin Pract. 2021 Oct; 36(5):927-941. View abstract
  2. Criticism of methods used in medication Y-site mixing study. Am J Health Syst Pharm. 2021 08 30; 78(17):1553-1554. View abstract
  3. Prevention and Management of Parenteral Nutrition-Associated Cholestasis and Intestinal Failure-Associated Liver Disease in the Critically Ill Infant. World Rev Nutr Diet. 2021; 122:379-399. View abstract
  4. ASPEN definitions in pediatric intestinal failure. JPEN J Parenter Enteral Nutr. 2021 Jul 21. View abstract
  5. Very Low Birthweight Preterm Infants: A 2020 Evidence Analysis Center Evidence-Based Nutrition Practice Guideline. J Acad Nutr Diet. 2021 Apr 02. View abstract
  6. One-year Experience With Composite Intravenous Lipid Emulsion in Children on Home Parenteral Nutrition. J Pediatr Gastroenterol Nutr. 2021 03 01; 72(3):451-455. View abstract
  7. Current strategies for managing intestinal failure-associated liver disease. Expert Opin Drug Saf. 2021 Mar; 20(3):307-320. View abstract
  8. Effect of Enteral Protein Amount on Growth and Health Outcomes in Very-Low-Birth-Weight Preterm Infants: Phase II of the Pre-B Project and an Evidence Analysis Center Systematic Review. J Acad Nutr Diet. 2020 Dec 22. View abstract
  9. The Power of Networking and Lessons Learned From Omegaven. J Pediatr Pharmacol Ther. 2020; 25(8):663-674. View abstract
  10. Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper. Nutr Clin Pract. 2021 Feb; 36(1):29-39. View abstract
  11. Fish Oil Emulsion Reduces Liver Injury and Liver Transplantation in Children with Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Study. J Pediatr. 2021 03; 230:46-54.e2. View abstract
  12. Optimizing Duration of Empiric Management of Suspected Central Line-Associated Bloodstream Infections in Pediatric Patients with Intestinal Failure. J Pediatr. 2020 12; 227:69-76.e3. View abstract
  13. ASPEN Lipid Injectable Emulsion Safety Recommendations, Part 1: Background and Adult Considerations. Nutr Clin Pract. 2020 Oct; 35(5):769-782. View abstract
  14. ASPEN Consensus Recommendations for Refeeding Syndrome. Nutr Clin Pract. 2020 Apr; 35(2):178-195. View abstract
  15. Intravenous Fish Oil Monotherapy as a Source of Calories and Fatty Acids Promotes Age-Appropriate Growth in Pediatric Patients with Intestinal Failure-Associated Liver Disease. J Pediatr. 2020 04; 219:98-105.e4. View abstract
  16. Growth in Infants and Children With Intestinal Failure-associated Liver Disease Treated With Intravenous Fish Oil. J Pediatr Gastroenterol Nutr. 2020 02; 70(2):261-268. View abstract
  17. Growth in Infants and Children with Intestinal Failure Associated-Liver Disease Treated with Intravenous Fish Oil. J Pediatr Gastroenterol Nutr. 2019 Nov 06. View abstract
  18. Use of Fish Oil Intravenous Lipid Emulsions as Monotherapy in the Pediatric Intestinal Failure Patient: Beyond the Package Insert. Nutr Clin Pract. 2020 Feb; 35(1):108-118. View abstract
  19. Enteral and parenteral nutrition considerations in pediatric patients. Am J Health Syst Pharm. 2019 Sep 16; 76(19):1492-1510. View abstract
  20. Metabolic and Inflammatory Effects of an ?-3 Fatty Acid-Based Eucaloric Ketogenic Diet in Mice With Endotoxemia. JPEN J Parenter Enteral Nutr. 2019 11; 43(8):986-997. View abstract
  21. Alpha-tocopherol in intravenous lipid emulsions imparts hepatic protection in a murine model of hepatosteatosis induced by the enteral administration of a parenteral nutrition solution. PLoS One. 2019; 14(7):e0217155. View abstract
  22. Trends of INR and Fecal Excretion of Vitamin K During Cholestasis Reversal: Implications in the Treatment of Neonates With Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2020 07; 44(5):951-958. View abstract
  23. The evolving use of intravenous lipid emulsions in the neonatal intensive care unit. Semin Perinatol. 2019 11; 43(7):151155. View abstract
  24. Omega 3 Fatty Acids in Enteral Nutrition for Very Low Birth Weight Preterm Infants: A Systematic Review (P11-085-19). Curr Dev Nutr. 2019 Jun; 3(Suppl 1). View abstract
  25. Fish oil-based injectable lipid emulsions containing medium-chain triglycerides or added a-tocopherol offer anti-inflammatory benefits in a murine model of parenteral nutrition-induced liver injury. Am J Clin Nutr. 2019 04 01; 109(4):1038-1050. View abstract
  26. Fish oil protects the liver from parenteral nutrition-induced injury via GPR120-mediated PPAR? signaling. Prostaglandins Leukot Essent Fatty Acids. 2019 04; 143:8-14. View abstract
  27. A Diet With Docosahexaenoic and Arachidonic Acids as the Sole Source of Polyunsaturated Fatty Acids Is Sufficient to Support Visual, Cognitive, Motor, and Social Development in Mice. Front Neurosci. 2019; 13:72. View abstract
  28. An Intravenous Fish Oil-Based Lipid Emulsion Successfully Treats Intractable Pruritus and Cholestasis in a Patient with Microvillous Inclusion Disease. Hepatology. 2019 03; 69(3):1353-1356. View abstract
  29. A detailed guide to lipid therapy in intestinal failure. Semin Pediatr Surg. 2018 Aug; 27(4):242-255. View abstract
  30. Essential Fatty Acid Status in Surgical Infants Receiving Parenteral Nutrition With a Composite Lipid Emulsion: A Case Series. JPEN J Parenter Enteral Nutr. 2019 02; 43(2):305-310. View abstract
  31. Innovative Discharge Process for Families with Pediatric Short Bowel Syndrome: A Prospective Nonrandomized Trial. JPEN J Parenter Enteral Nutr. 2018 11; 42(8):1295-1303. View abstract
  32. Standardized Competencies for Parenteral Nutrition Administration: The ASPEN Model. Nutr Clin Pract. 2018 Apr; 33(2):295-304. View abstract
  33. Pretreatment with intravenous fish oil reduces hepatic ischemia reperfusion injury in a murine model. Surgery. 2018 05; 163(5):1035-1039. View abstract
  34. Parenteral Soybean Oil Induces Hepatosteatosis Despite Addition of Fish Oil in a Mouse Model of Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2018 02; 42(2):403-411. View abstract
  35. Pediatric Intestinal Failure-Associated Liver Disease: Challenges in Identifying Clinically Relevant Biomarkers. JPEN J Parenter Enteral Nutr. 2018 02; 42(2):455-462. View abstract
  36. Characterization of Fatty Acid Profiles in Infants With Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2018 01; 42(1):71-77. View abstract
  37. Assessment of Micronutrient Status in Critically Ill Children: Challenges and Opportunities. Nutrients. 2017 Oct 28; 9(11). View abstract
  38. Blood and Hair Aluminum Levels, Vaccine History, and Early Infant Development: A Cross-Sectional Study. Acad Pediatr. 2018 03; 18(2):161-165. View abstract
  39. Home Parenteral Nutrition and Intravenous Fluid Errors Discovered Through Novel Clinical Practice of Reconciling Compounding Records: A Case Series. Nutr Clin Pract. 2017 Dec; 32(6):820-825. View abstract
  40. Lipid Injectable Emulsion Survey With Gap Analysis. Nutr Clin Pract. 2017 Oct; 32(5):694-702. View abstract
  41. Redefining essential fatty acids in the era of novel intravenous lipid emulsions. Clin Nutr. 2018 06; 37(3):784-789. View abstract
  42. Response to Driscoll. JPEN J Parenter Enteral Nutr. 2017 07; 41(5):704-705. View abstract
  43. Parenteral Nutrition Errors and Potential Errors Reported Over the Past 10 Years. Nutr Clin Pract. 2017 Dec; 32(6):826-830. View abstract
  44. Use of a novel docosahexaenoic acid formulation vs control in a neonatal porcine model of short bowel syndrome leads to greater intestinal absorption and higher systemic levels of DHA. Nutr Res. 2017 Mar; 39:51-60. View abstract
  45. Gastric Emptying in Critically Ill Children. JPEN J Parenter Enteral Nutr. 2017 09; 41(7):1100-1109. View abstract
  46. Methods to Reduce Medication Errors in a Clinical Trial of an Investigational Parenteral Medication. Contemp Clin Trials Commun. 2016 Dec 15; 4:64-67. View abstract
  47. Risk of post-procedural bleeding in children on intravenous fish oil. Am J Surg. 2017 Oct; 214(4):733-737. View abstract
  48. Pediatric Intestinal Failure-Associated Liver Disease: Challenges in Identifying Clinically Relevant Biomarkers. JPEN J Parenter Enteral Nutr. 2016 Sep 28. View abstract
  49. Intravenous Fat Emulsion Formulations for the Adult and Pediatric Patient: Understanding the Differences. Nutr Clin Pract. 2016 Oct; 31(5):596-609. View abstract
  50. Predictors of failure of fish-oil therapy for intestinal failure-associated liver disease in children. Am J Clin Nutr. 2016 09; 104(3):663-70. View abstract
  51. Higher Doses of Fish Oil-Based Lipid Emulsions Used to Treat Inadequate Weight Gain and Rising Triene:Tetraene Ratio in a Severely Malnourished Infant With Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2017 05; 41(4):667-671. View abstract
  52. A Comparison of Fish Oil Sources for Parenteral Lipid Emulsions in a Murine Model. JPEN J Parenter Enteral Nutr. 2017 02; 41(2):181-187. View abstract
  53. Discrepancies Between Prescribed and Actual Pediatric Home Parenteral Nutrition Solutions. Nutr Clin Pract. 2016 Oct; 31(5):654-8. View abstract
  54. Long-Term Fish Oil Lipid Emulsion Use in Children With Intestinal Failure-Associated Liver Disease [Formula: see text]. JPEN J Parenter Enteral Nutr. 2017 08; 41(6):930-937. View abstract
  55. Lipid emulsions in the treatment and prevention of parenteral nutrition-associated liver disease in infants and children. Am J Clin Nutr. 2016 Feb; 103(2):629S-34S. View abstract
  56. Nutritional status and feeding practices in gastrointestinal surgery patients at Bach Mai Hospital, Hanoi, Vietnam. Asia Pac J Clin Nutr. 2016; 25(3):513-20. View abstract
  57. Intravenous Lipid Emulsions in Parenteral Nutrition. Adv Nutr. 2015 Sep; 6(5):600-10. View abstract
  58. Parenteral Nutrition L-Cysteine Product Shortage Considerations. Nutr Clin Pract. 2015 Aug; 30(4):579-80. View abstract
  59. Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation. Pediatr Blood Cancer. 2015 Apr; 62(4):687-92. View abstract
  60. Challenging the 48-Hour Rule-Out for Central Line-Associated Bloodstream Infections in the Pediatric Intestinal Failure Population: A Retrospective Pilot Study. JPEN J Parenter Enteral Nutr. 2016 05; 40(4):567-73. View abstract
  61. The natural history of cirrhosis from parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy. Ann Surg. 2015 Jan; 261(1):172-9. View abstract
  62. Update to A.S.P.E.N. position paper: clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2014 Dec; 29(6):841. View abstract
  63. Aluminum contamination in parenteral products. Curr Opin Clin Nutr Metab Care. 2014 Nov; 17(6):551-7. View abstract
  64. The addition of medium-chain triglycerides to a purified fish oil-based diet alters inflammatory profiles in mice. Metabolism. 2015 Feb; 64(2):274-82. View abstract
  65. Elevated Alkaline Phosphatase in Infants With Parenteral Nutrition-Associated Liver Disease Reflects Bone Rather Than Liver Disease. JPEN J Parenter Enteral Nutr. 2015 Nov; 39(8):973-6. View abstract
  66. Sterile product compounding using an i.v. compounding workflow management system at a pediatric hospital. Am J Health Syst Pharm. 2014 Aug 01; 71(15):1311-7. View abstract
  67. Neonates with short bowel syndrome: an optimistic future for parenteral nutrition independence. JAMA Surg. 2014 Jul; 149(7):663-70. View abstract
  68. Serum citrulline as a biomarker of gastrointestinal function during hematopoietic cell transplantation in children. J Pediatr Gastroenterol Nutr. 2014 Jun; 58(6):709-14. View abstract
  69. Going with the flow or swimming against the tide: should children with central venous catheters swim? Nutr Clin Pract. 2014 Feb; 29(1):97-109. View abstract
  70. Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions. Adv Nutr. 2013 Nov; 4(6):711-7. View abstract
  71. Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators. Am J Physiol Gastrointest Liver Physiol. 2013 Dec; 305(11):G818-28. View abstract
  72. Aspartate aminotransferase to platelet ratio index correlates with hepatic cirrhosis but not with fibrosis in pediatric patients with intestinal failure. J Pediatr Gastroenterol Nutr. 2013 Sep; 57(3):367-71. View abstract
  73. Role of parenteral lipid emulsions in the preterm infant. Early Hum Dev. 2013 Oct; 89 Suppl 2:S45-9. View abstract
  74. Parenteral nutrition intravenous fat emulsions product shortage considerations. Nutr Clin Pract. 2013 Aug; 28(4):528-9. View abstract
  75. A comparison of 2 intravenous lipid emulsions: interim analysis of a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2014 Aug; 38(6):693-701. View abstract
  76. A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for metabolic bone disease. JPEN J Parenter Enteral Nutr. 2013 Sep; 37(5):570-98. View abstract
  77. Mechanisms for the effects of fish oil lipid emulsions in the management of parenteral nutrition-associated liver disease. Prostaglandins Leukot Essent Fatty Acids. 2013 Sep; 89(4):153-8. View abstract
  78. A metabolomic analysis of two intravenous lipid emulsions in a murine model. PLoS One. 2013; 8(4):e59653. View abstract
  79. The use of fish oil lipid emulsion in the treatment of intestinal failure associated liver disease (IFALD). Nutrients. 2012 Nov 27; 4(12):1828-50. View abstract
  80. The role of the ?-3 fatty acid DHA in the human life cycle. JPEN J Parenter Enteral Nutr. 2013 Jan; 37(1):15-22. View abstract
  81. Response to Meyer and Gortner. JPEN J Parenter Enteral Nutr. 2013 Jan; 37(1):13-4. View abstract
  82. The effect of varying ratios of docosahexaenoic acid and arachidonic acid in the prevention and reversal of biochemical essential fatty acid deficiency in a murine model. Metabolism. 2013 Apr; 62(4):499-508. View abstract
  83. Response to the letter to the editor regarding Nutrition support of neonatal patients at risk for necrotizing enterocolitis. JPEN J Parenter Enteral Nutr. 2013 Jan; 37(1):12. View abstract
  84. Provision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates. JPEN J Parenter Enteral Nutr. 2013 Jul; 37(4):498-505. View abstract
  85. A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for necrotizing enterocolitis. JPEN J Parenter Enteral Nutr. 2012 Sep; 36(5):506-23. View abstract
  86. A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012 Apr; 27(2):150-92. View abstract
  87. Attenuation of resting energy expenditure following hematopoietic SCT in children. Bone Marrow Transplant. 2012 Oct; 47(10):1301-6. View abstract
  88. Effect of titrated parenteral nutrition on body composition after allogeneic hematopoietic stem cell transplantation in children: a double-blind, randomized, multicenter trial. Am J Clin Nutr. 2012 Feb; 95(2):342-51. View abstract
  89. A.S.P.E.N. Clinical Guidelines: hyperglycemia and hypoglycemia in the neonate receiving parenteral nutrition. JPEN J Parenter Enteral Nutr. 2012 Jan; 36(1):81-95. View abstract
  90. Use of an omega-3 fatty acid-based emulsion in the treatment of parenteral nutrition-induced cholestasis in patients with microvillous inclusion disease. J Pediatr Surg. 2011 Dec; 46(12):2376-82. View abstract
  91. Docosahexaenoic acid and arachidonic acid prevent essential fatty acid deficiency and hepatic steatosis. JPEN J Parenter Enteral Nutr. 2012 Jul; 36(4):431-41. View abstract
  92. Parenteral fish-oil-based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition-dependent children. Am J Clin Nutr. 2011 Sep; 94(3):749-58. View abstract
  93. Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model. J Pediatr Surg. 2011 Apr; 46(4):666-673. View abstract
  94. Parenteral fish oil as monotherapy improves lipid profiles in children with parenteral nutrition-associated liver disease. JPEN J Parenter Enteral Nutr. 2010 Sep-Oct; 34(5):477-84. View abstract
  95. Rapid infusion of fish oil-based emulsion in infants does not appear to be associated with fat overload syndrome. Nutr Clin Pract. 2010 Aug; 25(4):399-402. View abstract
  96. Assessing portal fibrosis in parenteral nutrition-dependent patients treated with omega-3 fatty acid lipid emulsion. J Pediatr. 2010 Sep; 157(3):517; author reply 518. View abstract
  97. Parenteral fish oil monotherapy in the management of patients with parenteral nutrition-associated liver disease. Arch Surg. 2010 Jun; 145(6):547-51. View abstract
  98. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. J Pediatr Surg. 2010 Jun; 45(6):1287-93. View abstract
  99. Aluminum contamination in products used in parenteral nutrition: has anything changed? Nutrition. 2010 Jun; 26(6):585-94. View abstract
  100. Innovative parenteral and enteral nutrition therapy for intestinal failure. Semin Pediatr Surg. 2010 Feb; 19(1):27-34. View abstract
  101. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr. 2010 Feb; 50(2):212-8. View abstract
  102. Effects of glucose or fat calories in total parenteral nutrition on fat metabolism and systemic inflammation in rats. Metabolism. 2011 Feb; 60(2):195-205. View abstract
  103. Parenteral nutrition in the critically ill patient. N Engl J Med. 2010 Jan 07; 362(1):81-2; author reply 83-4. View abstract
  104. A multi-center, randomized, controlled trial of parenteral nutrition titrated to resting energy expenditure in children undergoing hematopoietic stem cell transplantation ("PNTREE"): rationale and design. Contemp Clin Trials. 2010 Mar; 31(2):157-64. View abstract
  105. Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. Pediatr Res. 2009 Dec; 66(6):698-703. View abstract
  106. Is there still a role for peripheral parenteral nutrition? Nutr Clin Pract. 2009 Dec; 24(6):709-17. View abstract
  107. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009 Sep; 250(3):395-402. View abstract
  108. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009 Sep-Oct; 33(5):541-7. View abstract
  109. The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep; 81(2-3):165-70. View abstract
  110. Parenteral fish oil as monotherapy for patients with parenteral nutrition-associated liver disease. Pediatr Surg Int. 2009 Jan; 25(1):123-4. View abstract
  111. Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications. Metabolism. 2008 May; 57(5):698-707. View abstract
  112. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008 Mar; 121(3):e678-86. View abstract
  113. Re: Influence of different intravenous lipid emulsions on hepatobiliary dysfunction in a rabbit model. J Pediatr Gastroenterol Nutr. 2008 Feb; 46(2):224-5; author reply 225. View abstract
  114. The role of an intravenous fat emulsion composed of fish oil in a parenteral nutrition-dependent patient with hypertriglyceridemia. Nutr Clin Pract. 2007 Dec; 22(6):664-72. View abstract
  115. Pediatric intestinal failure: nutrition, pharmacologic, and surgical approaches. Nutr Clin Pract. 2007 Dec; 22(6):653-63. View abstract
  116. Better living through chemistry, constant monitoring, and prompt interventions: 26 years on home parenteral nutrition without major complications. Nutrition. 2008 Jan; 24(1):103-7. View abstract
  117. Omega-3 fatty acids and liver disease. Hepatology. 2007 Apr; 45(4):841-5. View abstract
  118. Current clinical applications of omega-6 and omega-3 fatty acids. Nutr Clin Pract. 2006 Aug; 21(4):323-41. View abstract
  119. Current Clinical Applications of O-6 and O-3 Fatty Acids. Nutr Clin Pract. 2006 Aug; 21(4):323-341. View abstract
  120. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol. 2006 Dec; 291(6):G1011-9. View abstract
  121. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006 Jul; 118(1):e197-201. View abstract
  122. Recent developments in aluminium contamination of products used in parenteral nutrition. Curr Opin Clin Nutr Metab Care. 2006 May; 9(3):239-46. View abstract
  123. Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis. Pediatr Surg Int. 2006 Jun; 22(6):562-4. View abstract
  124. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr. 2005 Oct; 24(5):839-47. View abstract
  125. The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg. 2005 Sep; 40(9):1446-53. View abstract
  126. The role of enteral nutrition in the reversal of parenteral nutrition-associated liver dysfunction in infants. J Pediatr Surg. 2005 Jun; 40(6):1015-8. View abstract
  127. Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation. 2005 Mar 15; 79(5):606-8. View abstract
  128. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar; 57(3):445-52. View abstract
  129. Glutamine supplementation in infants with gastrointestinal disease: a randomized, placebo-controlled pilot trial. Nutrition. 2004 Sep; 20(9):752-6. View abstract
  130. Incidence and nature of epidemic nosocomial infections. J Infus Nurs. 2004 May-Jun; 27(3):175-80. View abstract
  131. Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency. Hepatology. 2004 Apr; 39(4):1176-7; author reply 1177-8. View abstract
  132. Effectiveness of a clinical practice guideline for parenteral nutrition: a 5-year follow-up study in a pediatric teaching hospital. JPEN J Parenter Enteral Nutr. 2002 Nov-Dec; 26(6):377-81. View abstract
  133. Success rates and cost-effectiveness of antibiotic combinations for initial treatment of central-venous-line infections during total parenteral nutrition. JPEN J Parenter Enteral Nutr. 2000 Mar-Apr; 24(2):119-25. View abstract
  134. Procedures for preparing injectable medications for latex-sensitive patients. Am J Health Syst Pharm. 1997 Nov 01; 54(21):2516-7. View abstract
  135. Structural characterization of molecular phospholipid species in cytoplasmic membranes of the cell wall-less Streptomyces hygroscopicus L form by use of electrospray ionization coupled with collision-induced dissociation mass spectrometry. J Bacteriol. 1997 Jun; 179(11):3437-42. View abstract
  136. Lipid and fatty acid composition of cytoplasmic membranes from Streptomyces hygroscopicus and its stable protoplast-type L form. J Bacteriol. 1997 Jun; 179(11):3430-6. View abstract
  137. Central venous line related bacteremia during total parenteral nutrition and/or chemotherapy infusions in children. Ann Ig. 1997 Jan-Feb; 9(1):35-40. View abstract
  138. Aminosyn PF or trophamine: which provides more protection from cholestasis associated with total parenteral nutrition? J Pediatr Gastroenterol Nutr. 1995 Nov; 21(4):374-82. View abstract
  139. Parenteral drug administration guidelines for the pediatric patient: one hospital's recommendations. Hosp Pharm. 1993 Mar; 28(3):221-3, 227-8, 231-42. View abstract